Ibd 2024: Charting a New Course in IBD Proceedings of the Takeda Symposium 22-23 November 2024 W Hotel, Brisbane, Queensland, Australia

Uma Mahadevan; Vipul Jairath; Jakob Begun; Aviv Pudipeddi; Mayur Garg; Peter De Cruz; Christopher F. D. Li Wai Suen; Matthew C. Choy; Danny Con; Rose Vaughan; John D. Chetwood; David A. Clark; Craig Haifer; Miles P. Sparrow; Rupert Leong; Reme Mountifield

doi:10.1111/jgh.70020

Ibd 2024: Charting a New Course in IBD Proceedings of the Takeda Symposium 22-23 November 2024 W Hotel, Brisbane, Queensland, Australia

Uma Mahadevan, Vipul Jairath, Jakob Begun, Aviv Pudipeddi, Mayur Garg, Peter De Cruz, Christopher F. D. Li Wai Suen, Matthew C. Choy, Danny Con, Rose Vaughan, John D. Chetwood, David A. Clark, Craig Haifer, Miles P. Sparrow, Rupert Leong, Reme Mountifield

Research output: Contribution to journal › Review article › peer-review

3 Downloads (Pure)

Abstract

The symposium IBD 2024: Charting a New Course in IBD was held in Brisbane, Australia, in November 2024. This was the fifth such meeting for the Australian inflammatory bowel disease (IBD) healthcare community. This symposium provided an overview of current and emerging management strategies for ulcerative colitis (UC) and Crohn's disease (CD). Key topic areas covered included the importance of treating to a minimum of endoscopic remission; important considerations for treatment choice, treatment switch, and treatment de-escalation; treatment during pregnancy; and emerging therapeutic options. This supplement provides a detailed summary of each of the symposium presentations, as well as key take-home messages.

Original language	English
Pages (from-to)	3-22
Number of pages	20
Journal	Journal of Gastroenterology and Hepatology
Volume	40
Issue number	Suppl 3
DOIs	https://doi.org/10.1111/jgh.70020
Publication status	Published - Sept 2025

Bibliographical note

Copyright the Author(s) 2025. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.

Keywords

Crohn's disease
IBD
Emerging therapeutic options
Endoscopic remission
Ulcerative colitis

Access to Document

10.1111/jgh.70020Licence: CC BY-NC-ND

Publisher version (open access)Final published version, 474 KBLicence: CC BY-NC-ND

Cite this

Mahadevan, U., Jairath, V., Begun, J., Pudipeddi, A., Garg, M., De Cruz, P., Li Wai Suen, C. F. D., Choy, M. C., Con, D., Vaughan, R., Chetwood, J. D., Clark, D. A., Haifer, C., Sparrow, M. P., Leong, R., & Mountifield, R. (2025). Ibd 2024: Charting a New Course in IBD Proceedings of the Takeda Symposium 22-23 November 2024 W Hotel, Brisbane, Queensland, Australia. Journal of Gastroenterology and Hepatology, 40(Suppl 3), 3-22. https://doi.org/10.1111/jgh.70020

@article{ea5ec0fc0fa648a28bc59158bc5ca031,

title = "Ibd 2024: Charting a New Course in IBD Proceedings of the Takeda Symposium 22-23 November 2024 W Hotel, Brisbane, Queensland, Australia",

abstract = "The symposium IBD 2024: Charting a New Course in IBD was held in Brisbane, Australia, in November 2024. This was the fifth such meeting for the Australian inflammatory bowel disease (IBD) healthcare community. This symposium provided an overview of current and emerging management strategies for ulcerative colitis (UC) and Crohn's disease (CD). Key topic areas covered included the importance of treating to a minimum of endoscopic remission; important considerations for treatment choice, treatment switch, and treatment de-escalation; treatment during pregnancy; and emerging therapeutic options. This supplement provides a detailed summary of each of the symposium presentations, as well as key take-home messages.",

keywords = "Crohn's disease, IBD, Emerging therapeutic options, Endoscopic remission, Ulcerative colitis",

author = "Uma Mahadevan and Vipul Jairath and Jakob Begun and Aviv Pudipeddi and Mayur Garg and \{De Cruz\}, Peter and \{Li Wai Suen\}, \{Christopher F. D.\} and Choy, \{Matthew C.\} and Danny Con and Rose Vaughan and Chetwood, \{John D.\} and Clark, \{David A.\} and Craig Haifer and Sparrow, \{Miles P.\} and Rupert Leong and Reme Mountifield",

note = "Copyright the Author(s) 2025. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.",

year = "2025",

month = sep,

doi = "10.1111/jgh.70020",

language = "English",

volume = "40",

pages = "3--22",

journal = "Journal of Gastroenterology and Hepatology",

issn = "0815-9319",

publisher = "Wiley-Blackwell, Wiley",

number = "Suppl 3",

}

Mahadevan, U, Jairath, V, Begun, J, Pudipeddi, A, Garg, M, De Cruz, P, Li Wai Suen, CFD, Choy, MC, Con, D, Vaughan, R, Chetwood, JD, Clark, DA, Haifer, C, Sparrow, MP, Leong, R & Mountifield, R 2025, 'Ibd 2024: Charting a New Course in IBD Proceedings of the Takeda Symposium 22-23 November 2024 W Hotel, Brisbane, Queensland, Australia', Journal of Gastroenterology and Hepatology, vol. 40, no. Suppl 3, pp. 3-22. https://doi.org/10.1111/jgh.70020

TY - JOUR

T1 - Ibd 2024

T2 - Charting a New Course in IBD Proceedings of the Takeda Symposium 22-23 November 2024 W Hotel, Brisbane, Queensland, Australia

AU - Mahadevan, Uma

AU - Jairath, Vipul

AU - Begun, Jakob

AU - Pudipeddi, Aviv

AU - Garg, Mayur

AU - De Cruz, Peter

AU - Li Wai Suen, Christopher F. D.

AU - Choy, Matthew C.

AU - Con, Danny

AU - Vaughan, Rose

AU - Chetwood, John D.

AU - Clark, David A.

AU - Haifer, Craig

AU - Sparrow, Miles P.

AU - Leong, Rupert

AU - Mountifield, Reme

N1 - Copyright the Author(s) 2025. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.

PY - 2025/9

Y1 - 2025/9

N2 - The symposium IBD 2024: Charting a New Course in IBD was held in Brisbane, Australia, in November 2024. This was the fifth such meeting for the Australian inflammatory bowel disease (IBD) healthcare community. This symposium provided an overview of current and emerging management strategies for ulcerative colitis (UC) and Crohn's disease (CD). Key topic areas covered included the importance of treating to a minimum of endoscopic remission; important considerations for treatment choice, treatment switch, and treatment de-escalation; treatment during pregnancy; and emerging therapeutic options. This supplement provides a detailed summary of each of the symposium presentations, as well as key take-home messages.

AB - The symposium IBD 2024: Charting a New Course in IBD was held in Brisbane, Australia, in November 2024. This was the fifth such meeting for the Australian inflammatory bowel disease (IBD) healthcare community. This symposium provided an overview of current and emerging management strategies for ulcerative colitis (UC) and Crohn's disease (CD). Key topic areas covered included the importance of treating to a minimum of endoscopic remission; important considerations for treatment choice, treatment switch, and treatment de-escalation; treatment during pregnancy; and emerging therapeutic options. This supplement provides a detailed summary of each of the symposium presentations, as well as key take-home messages.

KW - Crohn's disease

KW - IBD

KW - Emerging therapeutic options

KW - Endoscopic remission

KW - Ulcerative colitis

UR - https://www.scopus.com/pages/publications/105018254376

U2 - 10.1111/jgh.70020

DO - 10.1111/jgh.70020

M3 - Review article

C2 - 41069245

SN - 0815-9319

VL - 40

SP - 3

EP - 22

JO - Journal of Gastroenterology and Hepatology

JF - Journal of Gastroenterology and Hepatology

IS - Suppl 3

ER -

Ibd 2024: Charting a New Course in IBD Proceedings of the Takeda Symposium 22-23 November 2024 W Hotel, Brisbane, Queensland, Australia

Abstract

Bibliographical note

Keywords

Access to Document

Other files and links

Fingerprint

Cite this